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Summary 
Interleukin (IL)-12 synergizes with other cytokines to stimulate the proliferation and differentia- 
tion of early hematopoietic progenitors in vitro. However, in vivo administration of IL-12 decreases 
peripheral blood counts and bone marrow hematopoiesis.  Here, we used interferon (IFN) 3/ 
receptor-deficient (IFN3,R -/-) mice to investigate whether the in vivo inhibition of hemato- 
poiesis  by IL-12 is indirectly mediated by IL-12-induced IFN-3'.  IL-12 administered for 4 d  (1 
/xg/mouse per day) resulted in lower peripheral blood counts and a 2-fold decrease in bone marrow 
cellularity in wild-type mice, but not in IFN'yR -/-  mice. Bone marrow hematopoietic pro- 
genitors  were  decreased  after  IL-12 treatment  in  wild-type  mice,  but  rather  increased  in 
IFN~/Ik -/- mice. Splenic cellularity was 2.3-fold higher after IL-12 administration in wild-type 
mice, largely due to natural killer (NK) cell and macrophage infiltration together with some 
extramedullary hematopoiesis. In IFNyR -/-  mice, spleen cellularity was less increased, there 
were fewer infiltrating NK cells, but a strong extramedullary hematopoiesis. Thus, alterations 
mediated by IL-12-induced IFN-3, include reduction in bone marrow cellularity and hematopoi- 
etic progenitors,  as well as pronounced splenomegaly, largely caused by NK cell infiltration. 
In the absence of IFN-y signaling, IL-12 promotes hematopoiesis, consistent with its in vitro 
activities. 
I 
L-12 is a heterodimeric cytokine that affects the growth 
and function of T  and NK cells (1-4,  for review see 5). 
Studies with human and murine cells have shown IL-12 to 
promote the development of Thl cells, induce the secretion 
of IFN-3' from resting and activated T  and NK cells, func- 
tion as growth factor of T  and NK cells, and enhance the 
cytolytic activity of NK cells and cytotoxic lymphocytes (6-10). 
In addition,  IL-12 synergizes with other cytokines such as 
kit ligand (KL), IL-3, and IL-11 in stimulating the prolifera- 
tion and differentiation of early hematopoietic progenitors 
in vitro (11-14). 
In contrast to the stimulation of hematopoietic cells seen 
in vitro, IL-12 administration reportedly induced neutropenia, 
lymphopenia, and anemia in mice (unpublished observations 
reviewed in reference 5). Here, we confirm these results and 
further document a marked reduction in bone marrow cel- 
lularity  together  with  a  lower  content  in  hematopoietic 
precursor after IL-12 administration in mice. The apparent 
discrepancy between in vitro and in vivo effects of IL-12 on 
hematopoiesis may be explained by invoking secondarily pro- 
duced antagonistic cytokines. 
IL-12 was shown to strongly stimulate the transcription 
and secretion of IFN-3, by T cells and NK ceils both in vitro 
(1, 8, 15) and in vivo (16, 17). IL-12 also induces TNF-c~ and 
IL-10 gene transcription in vivo (16).  In contrast, IL-3 and 
IL-4 gene expression are suppressed after IL-12 treatment (16). 
Enriched human NK cells stimulated with IL-12 were recently 
reported to inhibit hematopoietic colony formation from bone 
marrow cells (18). This was attributed to IL-12-induced ex- 
pression of IFN-3, and TNF-ot by NK cells, suggesting that 
secondary cytokine production by lymphoid cells may play 
a role in the regulation of hematopoiesis (18). IFN-3' has been 
reported to be a negative hematopoietic and lymphopoietic 
regulator, based both on in vitro data (19-22) and on results 
obtained in vivo in mice and primates (for review see refer- 
ence 23). The inhibitory effects of IL-12 treatment on in vivo 
hematopoiesis could therefore be a result of the IL-12-induced 
production of IFN-3,. In this study, IFN-3, receptor-deficient 
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tiate between the respective effects of IL-12  and  IFN-3,  on 
hematopoiesis  in  vivo. 
Materials and Methods 
Reagents.  The following recombinant human (h) and murine 
(m) cytokines were used: hlL1B, raiL-3, and mKL (Sandoz Pharma 
Ltd., Basel,  Swizerland), hlL-11 (Genetics Institute,  Cambridge, 
MA), and raiL-12 (Hoffmann-LaRoche, Nutley, NJ) (16). The an- 
tibodies used were rat mAb anti-mouse CDllb (Mac-l; BMA Bio- 
medicals, Augst, Switzerland),  mAb NKI.I-FITC conjugate (Phar- 
Mingen, San Diego, CA), goat Ig anti-rat IgG conjugated to PE 
(Southern Biotechnology Associates,  Birmingham, AL), and rat 
mAb anti-mouse macrophage IgG (F4/80; American Tissue Cul- 
ture Collection, Rockville, MD). 
In vivo treatments.  7-10-wk-old 129 Sv/Ev wild-type and IFN-y 
receptor-deficient mice (24),  bred and maintained under specific 
pathogen-free conditions, were injected intraperitoneally with either 
saline or mlL-12 (1 ~g/mouse per d) for 4 or 7 consecutive days, 
as indicated.  Blood was collected from the retroorbital sinus 24 h 
after the last  injection. 
Hematology and Cytology.  Standard hemograms were performed 
with fresh heparinized blood on a hematology analyzer (Sysmex 
E-2500; Digitana, Switzerland). Reticulocytes were stained using 
thiazole orange (Becton Dickinson & Co., San Jose, CA) and were 
quantified by flow cytometry as percentage of erythrocytes. Blood 
smears stained with DIFF-QUIK  |  (Dade, Dfidingen, Switzerland) 
were read in parallel.  Cytospin preparations of bone marrow and 
spleen cells were stained with May-Gr/inwald-Giemsa,  and differen- 
tial  analyses were performed on 300-500 cells. 
Determination of  Plasma IFN-  7 Levels.  Murine IFN-'y was ana- 
lyzed by double sandwich ELISA (according to the method of Dr. 
L. Ozmen, Hoffmann-La Roche, Basel, Switzerland).  Briefly, plates 
were coated with anti-mouse IFN-3' rat mAb AN18 (25; 10/~g/ml 
in 0.1  M NaHCOa,  pH 9.5) and blocked with 1% BSA in PBS 
(PBS/BSA). Samples and standards were added in combination with 
anti-mouse IFN-'y rat mAb XMG 1.2 coupled to peroxidase  (26) 
in PBS/BSA  and incubated overnight at room temperature. The 
reaction was developed with orthophenyldiamine substrate (Sigma 
Chemical Co., St. Louis, MO) and absorbance at 495 nm was read. 
Flow Cytometric Analysis.  Bone marrow and spleen cells were 
washed,  stained  with  anti-mouse  CDllb  antibodies  (45  min), 
washed  three times,  and further labeled  with anti-rat  IgG PE- 
conjugated Ig (30 min). Alternatively, an NKI.1 antibody-FITC 
conjugate was incubated for 45 min.  Fluorescence analyses were 
performed on a FACScan  |  (Becton Dickinson & Co.) using Lysis 
II software. 
Colony Assays from Spleen and Bone Marrow Cells.  Cell suspen- 
sions from bone marrow and spleen prepared in isotonic balanced 
salt solution were counted in cytology chambers using Turk's col- 
oration.  Methylcellulose cultures were prepared in IMDM con- 
taining 4% FCS, BSA fraction V, transferrin, and lipids according 
to Iscove et al.  (27) in the presence of optimized concentrations 
of erythropoietin (Epo; 0.08 U/ml) with either IL-3 (30 ng/ml) 
and IL-1 (10 ng/ml), or II.-11 (50/zl COS supernatant/ml) and KL 
(25/z] COS supernatant/ml), as indicated. Cells from treated mice 
were pooled for each group,  and several concentrations of bone 
marrow  (3-20  x  104  cells/ml)  and  spleen  cells  (1-3  x  105 
cells/ml) were titrated in triplicate for each pool to ensure sufficient 
number of colonies per culture. Large (>1 mm) multilineage colo- 
nies comprising erythroid, megakaryocytic, and other myeloid cells, 
erythroid colonies (either pure or containing megakaryocytes)  and 
GM colonies were counted on day 9. The colonies were identified 
by their morphology and were periodically picked,  spread,  and 
stained (Wright-Giemsa) for confirmation. Results from three to 
six culture plates  are combined for each  determination. 
Statistics.  All results  are pooled from two independent experi- 
ments and are expressed  as mean  +  SD with n  =  4-8 animals 
per group.  They were compared using the student's t test,  and 
p <0.05 was  considered statistically  significant. 
Results and Discussion 
Since in vivo IL-12 administration was reported to induce 
neutropenia, lymphopenia, and anemia (5), we investigated 
the effect of IL-12  on hematopoiesis in normal  mice.  Mice 
were treated with  1 #g/mouse  per  d  IL-12,  a  dose shown 
to give maximal effect on NK cell cytotoxic function (17), 
daily for 7 d  and killed on day 8.  Bone marrow cellularity 
was reduced from 12.5  _+  2.5 million cells per femur in the 
placebo-treated  mice to  4.8  _+  1.1  million  cells per  femur 
in mice treated with IL-12  (n  =  6).  The frequency of bone 
marrow colony-forming hematopoietic progenitors  (CFC) 
was also reduced by two- to fourfold after IL-12 treatment 
(not shown).  The number of bone marrow cells per femur 
were already decreased by half, and the CFCs were reduced 
after 4 d of IL-12 treatment (see below; Figs.  I and 2). Thus, 
in line with the depressed blood counts reported after IL-12 
administration,  we  show  that  a  short  course  of II.-12  was 
strongly myelodepressive in wild-type  mice. 
There was  an apparent  discrepancy between  the in vivo 
myelotoxicity of IL-12 and its positive effects on hematopoi- 
etic progenitors in vitro. Indeed, in vitro, IL-12 was shown 
to synergize with other cytokines such as KL, IL-3, and IL-11 
to stimulate the proliferation and differentiation of early he- 
matopoietic progenitors (11,  13,  14,  18). These results were 
obtained with highly purified progenitors or even single cells, 
thus under conditions where the IL-12 effects observed were 
likely to be direct.  IL-12 myelotoxicity in vivo could,  how- 
ever, be explained by some indirect mechanisms.  Since IL-12 
has a profound stimulatory effect on IFN-3' production by 
T  cells and  NK cells both in vitro  (1,  8)  and  in vivo (16, 
17),  we hypothesized that  the inhibition  of hematopoiesis 
Figure I.  Effect  of IL-12 on bone marrow cellularity in wild-type and 
IFN'TR  -/-  mice. Wild-type  or  IFN'yR -/-  mice were treated with 
placebo or IL-12 (1/tg/mouse per d) for 4 d. The number of nucleated 
bone marrow cells per femur was determined on day 5. Student's t test 
*p  =  0.001. 
1894  1612 and IFN-3' in Hematopoiesis Figure  2.  Effect  of IL-12 on bone marrow hematopoietic progenitors 
in wild-type and IFNyR -/-  mice. Mice were treated as in Fig. 1. The 
number of multilineage (black bars), erythroid (light gray bars), and GM 
(dark gray bars) colony-forming  cells per femur on day 5 was determined 
in methylcellulose  cultures  containing  IL-11,  KL, and Epo. Results are from 
two experiments with pooled bone marrow cells per group. Student's t 
test/, >0.05. Similar results were obtained in cultures containing I1,-3, 
IL-1, and Epo (not shown). 
seen in vivo after IL-12 administration could be mediated by 
IL-12-induced  IFN-%  IFN-y  plasma  levels  were  indeed 
strongly increased after 4 d of ILo12 administration to normal 
mice (from 0.9  +  1.5  to 20.1  _+  9.1  ng/ml,  n  =  8).  Ad- 
ministration of IFN-y to mice is clearly myelosuppressive (for 
review see reference 23),  and IFN-'y was shown to suppress 
hematopoietic colony formation in vitro, either directly (19, 
21)  or when  secondarily induced  in  culture by ILl2  (18). 
We then examined the effect of II,-12  treatment  in mice 
rendered unresponsive to IFN-y after inactivation of the IFN-'y 
receptor gene (24). First, we established that untreated IFN-'y 
receptor-deficient (IFNyR -/-) mice maintained under SPF 
conditions have essentially normal hematopoietic parameters 
in  terms  of bone marrow  cellularity  and  CFC  content,  as 
well as spleen weight, cellularity, and number of CFC (not 
shown).  Wild-type and IFN'yR -/-  mice were then treated 
for 4  d  with  1 #g/mouse  per d  of IL-12  and killed on day 
5. In wild-type mice, this treatment resulted in mild anemia 
with reticulocytosis, some lymphopenia,  and a 3.3-fold de- 
crease in neutrophils (Table 1).  In IFNyR -/-  mice, the only 
significant change of peripheral blood counts observed after 
IL-12 treatment was a 1.8-fold increase of neutrophil counts 
(Table 1),  although  the levels of circulating IFN-3' were as 
high as 1,036  -+  322 ng/ml after IIA2 treatment (compared 
with 0.9  +  1.5 ng/ml in placebo-treated controls, n  =  8). 
There was  a significant twofold reduction in bone marrow 
cellularity in  IL-12-treated wild-type  mice compared with 
the placebo-treated controls (Fig. 1). In contrast, bone marrow 
cellularity was not significantly affected after IL12 treatment 
in IFNyR -/-  mice (Fig.  1).  Thus, the reduction of periph- 
eral blood cells and the overall decrease in bone marrow cel- 
lularity seen after IL-12 administration  seemed to be medi- 
ated by IFN-y. 
Cytological analysis of bone marrow preparations confirmed 
that the nonmitotic mature bone marrow cell population was 
markedly depleted in wild-type but not in IFN'yR -/-  mice 
treated with  IL-12  for 4  d.  In wild-type  mice,  IL-12  treat- 
ment resulted in a significant 11.2-fold reduction of erythroid 
elements and 4.7-fold depletion of lymphoid cells, plus a slight 
nonsignificant  reduction  of neutrophilic  and  eosinophilic 
precursors,  respectively  (Table  2).  Identifiable  monocytic 
precursors were significantly increased by 2.2-fold, and both 
myeloblast and erythroblast numbers were normal (Table 2). 
In  IFN'yR -/-  mice,  however,  IL-12  treatment  caused  only 
a slight, nonstatistically significant decrease in erythroid and 
lymphoid elements (Table 2). Neutrophilic precursors were 
2.9-fold decreased, while monocytic precursors were 1.5-fold 
increased (Table 2). In contrast to wild-type mice, there was 
a significant increase in eosinophilic precursors (1.6-fold) and 
blasts (2.2-fold, predominantly myeloblasts) after IL-12 treat- 
ment  of IFNyR -/-  mice.  Thus,  although  IL-12  induced 
monocytopoiesis  in  both  wild-type  and  IFN3,R -/-  mice, 
the suppression of most other cell lineages was absent or less 
severe in IFNyR -/-  mice, and blasts were increased only in 
mice that  were unresponsive  to  IFN-'y. 
We next studied the effect of a 4-d I1,-12 treatment on he- 
matopoietic  progenitors.  In  wild-type  mice,  the  absolute 
numbers of erythroid- and GM-CFC per femur were three- 
to fivefold decreased after IL-12 treatment, although this differ- 
ence, based on two experiments with pooled bone marrow 
cells  within  groups  of  mice,  did  not  reach  statistical 
Table  1.  Hematologic  Alterations  in IL-I2-treated  Wild-type and IFNy -/-  Mice 
Mouse  In vivo  Lymph-  Mono- 
genotype  treatment  WBC  RBC  Reticulocytes  Platelets  ocytes  Neutrophils  cytes  Eosinophils 
IFNyR §  Placebo  7.8  +  2.0  9.2  _+  0.4  0.52  _+  0.08  348  _+  122  6.4  _+  2.4  1.35  _+  0.69  <0.1  0.07  _+  0.06 
IFNyR */+  IL-12  5.3  -+  1.8"  8.3  +  0.8*  0.79  _+  0.23  245  +_  76  4.8  +  1.6  0.41  +  0.30*  <0.1  0.06  _+  0.05 
IFN'yR -/-  Placebo  6.5  _+  1.0  9.2  -+  0.8  0.78  _+  0.23  350  _+  165  5.3  _+  0.4  0.95  _+  0.65 s  <0.1  0.14  _+  0.10 
IFN'yR -/-  IL-12  6.8  _+  1.5  9.0  _+  0.7  0.74  _+  0.17  248  _+  90  5.2  _+ 0.9  1.76  _+  1.26  <0.1  0.02  _+  0.03 
Mice were treated with placebo or IL-12 (1 /~g/d) daily for 4 d and blood was collected on day 5. 
WBC,  total leukocytes (x 103//~1); RBC,  total erythrocytes (x 106//zl), reticulocytes (x 106/~1), platelets, neutrophils, monocytes, eosinophils 
( x 103//.d). 
Student's t tests: p < *0.05, ~0.03, S0.04. 
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significance.  In  IFNTR -/-  mice  treated  with  Ib12,  there 
was no decrease but rather a trend to increase  all CFCs (Fig. 
2). Even though the total cellularity per femur was twofold 
decreased in the Ib12-treated wild-type mice, the frequency 
of CFC was still twofold lower in these mice compared to 
placebo-treated controls.  In contrast, the IL-12 treatment of 
IFN3~R-/-  mice resulted  in up to a twofold increase of CFC 
frequency without  decreasing  the total marrow cellularity. 
Therefore,  a  short  IL-12 treatment,  which  depresses  bone 
marrow hematopoietic progenitors in wild-type mice, tends 
to increase  these progenitors in mice rendered  unresponsive 
to  IFN-% 
Ib12 induced splenomegaly in wild-type  mice,  as spleen 
weight was 5.5-fold increased in wild-type mice treated  for 
7 d with  1 #g/mouse per d IL-12 (402.9  +  57.7 vs.  72.4  _+ 
12.7 mg in placebo-treated mice,  n  =  9, p  <0.001).  A  2.3- 
fold increased  splenic weight  was  already  seen  after  4  d  of 
IL-12 treatment in wild-type mice (187.0  +  30.9 vs. 81.4  _+ 
15.9 mg, n  =  8 and 5,  respectively,  p <0.001).  Splenic cel- 
lularity was also 2.3-fold  increased  in these mice compared 
with placebo-treated animals (Fig. 3). This was due, at least 
in part,  to monocytic infiltrates  and a high NK cell content 
(histology not shown). FACS  |  analysis  from splenocyte sus- 
pensions  also  showed  a  doubling  of CDllb +  cells  and  a 
threefold increase  of NKI.1 + cells (Fig. 4).  Splenic hemato- 
poiesis was slightly increased after 4 d of IL-12 treatment as 
seen histologically (not shown) and by some increase  in the 
absolute  number  of  splenic  CFC,  which  did  not  reach 
stastistical  significance (Fig. 5). Thus, in wild-type mice, IL- 
12 induces  splenomegaly,  which  is  caused by both macro- 
phage and NK cell infiltration  in addition to some extramedul- 
lary hematopoiesis. 
IL-12-induced  splenomegaly  was  less  pronounced  in 
IFN3,R -/-  mice,  since 7 d of IL-12 treatment resulted only 
in a 1.7-fold increase in spleen weight (125.7  +  25.4 vs. 72.0  + 
13.1  mg,  n  =  6, p  =  0.001).  A  similar  spleen weight  in- 
crease  was  already  seen  after  4  d  of  IL-12 treatment  in 
IFN3,R -/-  mice  (150.8  +  25.4  vs.  77.5  +  17.9  mg,  n  = 
8 and 4, respectively, p <0.001). Splenic cellularity was slightly 
increased  in these animals, but this did not reach  statistical 
Figure  3.  Effect  of  IL-12 on  spleen  cellularity  in  wild-type  and 
IFN3,R -/-  mice.  Mice  were treated as in  Fig.  1,  and the total number 
of nucleated cells per spleen was determined on day 5. Student's t test  *p  = 
0.002. 
1896  IL-12 and IFN-3,  in  Hematopoiesis Figure 4.  Flow  cytometric  analysis  of spleen cells from wild-type  and 
IFN'yR  -/- mice treated with IL-12. Mice were treated as in Fig. 1. On 
day 5, splenocytes  were  harvested, stained  with anti CDllb (A) or NKI.1 
(B) antibodies, and analyzed  by flow cytometry. 
significance (Fig. 3). FACS  |  analysis from splenocyte suspen- 
sion showed a doubling of CD11b § cells but no increase in 
NKI.1 + cells in IL-12-treated  IFN3,R -/- mice (Fig. 4). The 
total number of CFC per spleen was increased in these mice 
after 4 d of IL-12 treatment, and this was particularly sig- 
nificant for erythroid CFC (Fig. 5). The frequency of CFC 
on a per cell basis was also 3.7-fold increased  in the IL-12 
treated IFN3~R -/-  mice, compared with 1.7-fold only in the 
wild-type mice. Therefore, the increases in splenic weight, 
cellularity, and NK cell infiltration after IL-12 treatment were 
less pronounced in IFN3,R -/- mice than in wild-type mice. 
In contrast, the frequency and the absolute number of splenic 
CFC were higher after IL-12 treatment in IFN3,R -/-  than 
in wild-type mice. 
In conclusion, the effects attributable to IFN-3~ after IL-12 
treatment include the reduction in bone marrow total cel- 
lularity, in identifiable myeloid, erythroid, and lymphoid ele- 
ments and in hematopoietic colony-forming  progenitors, and 
the dramatic increase of splenic cellularity, mainly due to NK 
cell  and macrophage infiltration. In an environment non- 
responsive  to  IFN-%  ILo12 does  not  reduce mature bone 
marrow cells,  moderately affects identifiable myeloid, ery- 
throid and lymphoid elements, and tends to increase blasts 
and colony-forming progenitors in the bone marrow. Splenic 
hematopoiesis is also increased  in IL-12-treated IFNq~R -/- 
Figure  5.  Effect  of IL-12 on splenic hematopoiesis  in wild-type and 
IFNyR-/- mice. Spleen  cells from wild-type  or IFN3,R  -/- mice  treated 
as in Fig. I were  harvested  on day 5, and the number  of  multilineage  (black 
bars), erythroid  (light  gray bars), and GM (dark gray bars) colony-forming 
cells per spleen  was determined  in methylcellulose  cultures  containing  IL- 
11, KL, and Epo. Results  are from two experiments  with pooled spleen 
cells per group. Student's t test *p = 0.04. Similar  results were obtained 
in cultures containing IL-1, IL-3, and Epo (not shown). 
mice, although there is a more moderate increase in splenic 
total cellularity with a markedly lower NK cell content. It 
seems that, in the absence of IFN-y signaling, an important 
costimulatory signal is missing to allow full stimulation of 
NK cell proliferation by IL-12. 
The results obtained in the absence of the IFN-y negative 
regulation in mice rendered deficient for IFN-3~ receptor are 
therefore compatible with the direct stimulation of early he- 
matopoietic progenitors by ILo12 seen in vitro (12-14). How- 
ever, the enhancement of bone marrow progenitors stimu- 
lated by IL-12 appears to be balanced in vivo by the production 
of IFN-% which acts in a dominant myelosuppressive fashion. 
Thus, although IFN-3~ does not seem to be essential for steady- 
state hematopoiesis, as seen in mice deficient for IFN-y produc- 
tion (28) or signaling (24), we demonstrate here that IFN-y 
is clearly a potent negative regulator of hematopoiesis when 
induced in response  to IL-12. Since high levels of IL-12 are 
produced  systemically during  endotoxemia,  this  negative 
regulatory function of IFN-y is likely to be of pathophysio- 
logical significance for the acute hematological alterations seen 
after bacterial infections. 
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